No data to show
XNAS
ABCL
Market cap1.13bUSD
Jun 25, Last price
3.80USD
1D
3.26%
1Q
61.02%
IPO
-92.40%
Name
Abcellera Biologics Inc
Chart & Performance
P/E
—
P/S
39.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.82%
Rev. gr., 5y
19.95%
Revenues
29m
-24.17%
Net income
-163m
L+11.24%
CFO
-109m
L+147.41%
Earnings
Aug 04, 2025
Profile
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 28,833 -24.17% | 38,025 -92.17% | 485,424 29.38% | ||||
Cost of revenue | 252,749 | 250,837 | 241,070 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (223,916) | (212,812) | 244,354 | ||||
NOPBT Margin | 50.34% | ||||||
Operating Taxes | (37,538) | (27,631) | 80,580 | ||||
Tax Rate | 32.98% | ||||||
NOPAT | (186,378) | (185,181) | 163,774 | ||||
Net income | (162,857) 11.24% | (146,398) -192.35% | 158,519 3.29% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 6,158 | 5,583 | |||||
Long-term debt | 121,486 | 148,602 | 153,350 | ||||
Deferred revenue | 8,195 | 60,317 | |||||
Other long-term liabilities | 80,450 | 106,734 | 19,140 | ||||
Net debt | (586,425) | (671,763) | (800,074) | ||||
| Cash flow | |||||||
Cash from operating activities | (108,556) | (43,877) | 277,360 | ||||
CAPEX | (78,396) | (77,507) | (72,660) | ||||
Cash from investing activities | 121,409 | (221,108) | (352,625) | ||||
Cash from financing activities | 12,769 | 10,356 | (1,628) | ||||
FCF | (346,769) | (252,821) | 121,805 | ||||
| Balance | |||||||
Cash | 625,614 | 760,585 | 886,485 | ||||
Long term investments | 82,297 | 65,938 | 72,522 | ||||
Excess cash | 706,469 | 824,622 | 934,736 | ||||
Stockholders' equity | 772,793 | 1,031,266 | 1,159,159 | ||||
Invested Capital | 567,420 | 520,005 | 460,256 | ||||
ROIC | 39.26% | ||||||
ROCE | 17.11% | ||||||
| EV | |||||||
Common stock shares outstanding | 294,328 | 289,166 | 314,827 | ||||
Price | 2.93 -48.69% | 5.71 -43.63% | 10.13 -29.16% | ||||
Market cap | 862,380 -47.77% | 1,651,141 -48.23% | 3,189,200 -29.93% | ||||
EV | 275,955 | 979,378 | 2,389,126 | ||||
EBITDA | (133,067) | (181,918) | 277,456 | ||||
EV/EBITDA | 8.61 | ||||||
Interest | 4,045 | ||||||
Interest/NOPBT | 1.66% | ||||||